Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721156 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
A Phase 2 study of Alzheimer Disease and Dementia, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06721156: Active Phase 2 study of Alzheimer Disease and Dementia, sponsored by Merck Sharp & Dohme.
NCT06721156 is a Phase 2 study of Alzheimer Disease and Dementia that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 350 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721156, a Phase 2 study of Alzheimer Disease and Dementia, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About the safety of MK-1167 and if people tolerate it
Primary Outcome
The change from baseline in ADAS-Cog11 score at Week 24 is presented. ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MK-1167
Study Locations (20)
Florida
- JEM Research Institute / Headlands Research Network ( Site 0108) - Atlantis
- Brain Matters Research-Neurology ( Site 0150) - Delray Beach
- Neuropsychiatric Research Center of Southwest Florida ( Site 0152) - Fort Myers
- Indago Research & Health Center, Inc ( Site 0128) - Hialeah
- K2 Medical Research THE VILLAGES ( Site 0166) - Lady Lake
- K2 Medical Research ( Site 0103) - Maitland
- Premier Clinical Research Institute ( Site 0114) - Miami
- Aqualane Clinical Research ( Site 0116) - Naples
- Headlands Research Orlando ( Site 0169) - Orlando
- Brain Matters Research ( Site 0151) - Stuart
- K2 Medical Research ( Site 0165) - Tampa
California
- Irvine Clinical Research ( Site 0104) - Irvine
- Anderson Clinical Research ( Site 0164) - Redlands
- California Neuroscience Research ( Site 0118) - Sherman Oaks
Georgia
- Columbus Memory Center ( Site 0197) - Columbus
- CenExel iResearch, LLC ( Site 0134) - Savannah
Arizona
- Banner Alzheimer's Institute ( Site 0110) - Phoenix
Louisiana
- Tandem Clinical Research ( Site 0101) - Marrero
Maryland
- Pharmasite Research, Inc. ( Site 0167) - Baltimore
Michigan
- Quest Research Institute ( Site 0173) - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT06721156 still lists
NCT06721156 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06721156 names 20 study sites across 7 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06721156 about?
NCT06721156 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)". Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the sta...
What is the current status of trial NCT06721156?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-12-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06721156 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia.
What interventions are being tested in trial NCT06721156?
The interventions under investigation include: Placebo (DRUG), MK-1167 (DRUG).
Who is sponsoring clinical trial NCT06721156?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721156 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721156's enrollment target sits among peer trials
350 75th of 306 higher than 231 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI